相关临床试验
195
65 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1957
进行中（未招募）
10
5.1%
已完成
21
10.8%
Enrolling By Invitation
4
2.0%
尚未招募
51
26.1%
招募中
53
27.2%
Temporarily Not Available
1
0.5%
终止
1
0.5%
Unknown
54
27.7%
暂无批准数据
- Everest Medicines unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day, showcasing a fully integrated system spanning antigen design to manufacturing. - The company's personalized cancer vaccine EVM16 demonstrated robust immunogenicity and mutation-specific T-cell responses in early clinical trials, while off-the-shelf vaccine EVM14 received FDA IND clearance. - Everest's innovative in vivo CAR-T program achieved high T-cell transduction efficiency and effective B-cell clearance in preclinical studies, offering a scalable alternative to conventional CAR-T therapies. - The company is pursuing global partnerships with top 20 pharmaceutical companies to accelerate international deployment of its clinically validated mRNA assets.
- A Chinese-developed drug combination of Benmelstobart and Anlotinib demonstrated superior efficacy over pembrolizumab (Keytruda) in treating PD-L1-positive advanced non-small cell lung cancer patients. - The combination therapy increased median progression-free survival by 3.9 months to 11 months total, with a 30% reduction in disease progression and death risk compared to the current standard treatment. - Results from the Phase III CAMPASS study involving over 500 patients were presented at the American Society of Clinical Oncology annual meeting as a Late-Breaking Abstract. - The achievement marks a potential shift from Chinese pharmaceutical companies being followers to leaders in international cancer treatment development.
- Shanghai Chest Hospital will begin a clinical trial in January to assess a novel CAR-T cell therapy for lung cancer, aiming to enroll 20 patients in the first phase. - The trial leverages CAR-T, an immunotherapy that reprograms a patient's immune cells to target and combat their specific cancer. - Chinese researchers have made significant strides in lung cancer treatment, achieving parity with developed countries in providing advanced therapies to patients. - Dr. Lu Shun's work on EGFR-mutated lung cancer has established a globally recognized "China Plan" for precise and innovative treatment.
